Study Links ADHD to Higher Mortality Risk
A large meta-analysis finds adults and children with ADHD face elevated risks of death from suicide, injury and natural causes.
Updated on Nov. 3, 2026 in Mental Health
A systematic review and meta-analysis published online October 19 in JAMA Network Open found ADHD is associated with a 71% higher risk of all-cause mortality. The analysis drew on nearly 16 million participants across 19 studies in seven countries.
Why it matters
The findings add quantitative weight to concerns that ADHD carries broader health consequences than its core symptoms suggest. Researchers noted no prior review had assessed the magnitude of mortality risk associated with the condition.
The meta-analysis pooled hazard ratios from 12 of 19 included studies covering nearly 16 million participants, with ADHD medication use linked to a 25% lower all-cause mortality hazard (HR 0.75). The medication estimate draws on only three studies, and causality cannot be established from these pooled associations.
The players
Joshua Stott
Investigator at University College London who co-led the meta-analysis of ADHD-related mortality.
David Goodman
Commentator at Johns Hopkins University School of Medicine who is a noted ADHD clinician and researcher.
The details
Investigators conducted a systematic review and meta-analysis of 19 studies in seven countries and used random-effects models to estimate pooled hazard ratios. Elevated risks were observed across suicide, injury and natural-cause deaths, with ADHD medication use associated with lower all-cause mortality among participants with the condition.
Timeline
• October 19: Meta-analysis published online in JAMA Network Open.
Health Landscape
The review fills a gap in the peer-reviewed literature on ADHD, since no prior systematic review had quantified mortality risk for the condition. It places ADHD alongside other conditions whose long-term survival effects are now being measured at population scale.
Adults and children with ADHD may consider discussing long-term health risks, including suicide and injury, with their clinicians. The medication association suggests treatment decisions can factor into mortality outcomes, though individual assessment with a provider remains necessary.
The takeaway
Clinicians and patients should weigh the elevated mortality associations alongside ADHD treatment and safety planning. Ongoing monitoring of suicide and injury risk appears warranted for people living with the condition.
Further reading
Explore more on Mental Health for broader context on how neurodevelopmental conditions relate to long-term outcomes.
Source note: This article includes information reported by Medscape.
